6533b86efe1ef96bd12cb2f8

RESEARCH PRODUCT

SY09EXPLORING CURRENT AND PROMISING PHARMACOTHERAPIES IN THE TREATMENT OF ALCOHOLISM: CLINICAL AND PRECLINICAL EVIDENCESY09-1COMBINED THERAPIES DO MATTER: OPTIMIZING NALTREXONE ANTI-RELAPSE EFFECT

Ana PolacheM. J. Sánchez-catalánLucía HipólitoM. J. Cano-cebriánLuis GraneroAlejandro OrricoLucía Martí-pratsTeodoro Zornoza

subject

Drugmedicine.medical_specialtymedicine.drug_classbusiness.industrymedia_common.quotation_subjectGeneral MedicineNaltrexoneClinical trialOpioid receptorInternal medicinemedicineIn patientPsychiatrybusinessmedicine.drugmedia_common

description

Naltrexone (NTX), a non-selective opioid receptor, is a licensed drug for treating alcohol use disorders almost from 20 years ago. During this time, more than 50 clinical trials have been conducted to evaluate its effects in patients suffering for alcoholism. Although these studies have confirmed its effectiveness, …

https://doi.org/10.1093/alcalc/agv076.34